DEA Classifies Synthetic Cannabinoid HHC as Illegal Schedule I Substance

The Drug Enforcement Administration (DEA) has issued a formal clarification that the synthetic cannabinoid hexahydrocannabinol (HHC) is considered an illegal Schedule I substance, not a legal hemp derivative. According to a recent Federal Register notice, HHC will now be assigned a unique drug code for federal classification, marking a significant move in the ongoing debate over synthetic cannabinoids and their legal status across the United States. This decision comes amid increasing scrutiny of novel cannabinoids that have emerged in the market, often marketed as hemp-derived and therefore presumed legal under the 2018 Farm Bill

The DEA's position on HHC reflects growing concerns about the proliferation of synthetic cannabinoids and their potential risks. By assigning HHC a specific drug code and classifying it under Schedule I, the agency aims to clarify enforcement priorities and reduce confusion among manufacturers, retailers, and consumers. As reported by Marijuana Moment, this clarification is likely to impact businesses that have been producing or selling HHC products under the belief that they were compliant with federal hemp laws

This regulatory update occurs against a backdrop of shifting state and federal policies on cannabis and its derivatives. Several states, including Texas and California, have recently revisited their own rules on cannabinoids such as THCA, delta-8 THC, and others. For example, a Texas judge recently allowed continued sales of smokable hemp THCA flower through July 27, while the state's Supreme Court upheld the right of regulators to ban delta-8 THC. Meanwhile, California has streamlined processes for cannabis businesses to adapt to federal rescheduling changes, making it easier for them to transition licenses from recreational to medical use

Industry stakeholders and policymakers have expressed mixed reactions to the DEA's move. While some see it as a necessary step to address public health concerns, others worry about the impact on small businesses and consumer access. In related developments, Pennsylvania Governor Josh Shapiro criticized his opponent for opposing cannabis legalization, emphasizing the lost revenue that could support "our schools, public safety and small businesses." Meanwhile, Missouri is facing a class action lawsuit alleging cartel-like behavior among marijuana businesses, and Maryland recently extended a task force to ensure equitable access to psychedelic substances

For the global cannabis industry, the DEA's reclassification of HHC underscores the complex and rapidly evolving regulatory landscape for cannabinoids, both synthetic and naturally derived. This development highlights the importance of clear guidelines for emerging compounds and signals heightened enforcement at the federal level. From the OG Lab newsroom perspective, industry participants should monitor regulatory updates closely as agencies continue to define the boundaries of legal cannabinoid commerce in the U.S., with potential ripple effects in international markets